SM16, an Orally Active TGF- Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

Arteriosclerosis, Thrombosis, and Vascular Biology- United States

doi 10.1161/atvbaha.107.158030


Related search